About US
Contact us
-
EC grants approval for Bristol-Myers' Opdivo to treat renal cell carcinomaBristol-Myers Squibb has obtained approval from the European Commission (EC) for its Opdivo (nivolumab) for previously treated advanced renal cell carcinoma (RCC). RCC is the most common type of kidn2016/5/11
-
Gilead's Descovy receives FDA approval to treat HIVAmerican biopharmaceutical company Gilead Sciences has secured approval from the US Food and Drug Administration (FDA) for Descovy (emtricitabine 200mg/tenofovir alafenamide 25mg, F/TAF) to treat pati2016/5/10
-
EMA committee recommends approval of Amicus' Galafold to treat Fabry diseaseThe European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended a marketing authorisation of Amicus Therapeutics' Galafold (migalastat) to treat Fabry disea2016/5/10
-
Eli Lilly receives FDA Priority Review approval for olaratumabAmerican pharmaceutical company Eli Lilly and Company has received Priority Review approval from the US Food and Drug Administration (FDA) for its biologics license application (BLA) for olaratumab.2016/5/9
-
M&As this week: Precision for Medicine and VeristatPharmaceutical and healthcare companyPrecision for Medicinehas acquired Applied Immunology, a custom cell-based and immunoassay solutions provider. Precision for Medicine expects that the move will h2016/5/9
-
Roche's Gazyvaro gets EMA recommendation to treat rare white blood cell cancerThe European Medicines Agency (EMA) has recommended the extension of the authorised indication of Roche's Gazyvaro (obinutuzumab) to treat patients affected with follicular lymphoma. Gazyvaro must be2016/5/6
-
New KISS Lab Circulators on display at AnalyticaAt Analytica International Trade Fair and Conference, Huber will be showcasing its new solutions and further developments in temperature control for the research laboratory and process industries. Vi2016/5/6
-
NICE recommends Sanofi's Praluent as an effective treatment for bad cholesterolFrench pharmaceutical company Sanofi's Praluent (alirocumab) has been recommended by the National Institute for Health and Care Excellence (NICE) as an effective treatment option for people with inher2016/5/5
-
Report: Uncertain economic environment to affect Italy’s pharmaceutical industryItaly's pharmaceutical industry is set to decline by 2020 owing to its struggling economy, according to a new report published by GlobalData. Registering a negative compound annual growth rate of 3.3%2016/5/5
-
Biogen's Daclizumab receives positive opinion to treat multiple sclerosisUS biotechnology company Biogen has announced new data that reveals daclizumab's positive cognitive outcomes, targeted and reversible mechanism of action (MOA), and safety profile in patients sufferin2016/5/4